Evidence map›Paper›PMID 34279087›Full record

ReviewChemical reviews2021

Lipids and Lipid Derivatives for RNA Delivery.

Yuebao Zhang, Changzhen Sun, Chang Wang, Katarina E Jankovic, Yizhou Dong

Abstract readReview
In one paragraph

Review in Chemical reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 263 papers.

0numbers the graph read from it
0cells of the map it votes in
263citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

263 citing papers in PubMed.

  1. Cas12a chRDNA-mediatedMolecular therapy. Nucleic acids · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Bioactive lipid-derived nanoparticles for RNA delivery.Materials today (Kidlington, England) · 2026
    Article
  7. RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Single-ligand dual-targeting lipid nanoparticles for therapeutic mRNA delivery to glioblastoma across the blood-brain barrier.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

203 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuebao ZhangDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Changzhen SunDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Chang WangDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Katarina E JankovicDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.
Yizhou DongDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.ORCID 0000-0001-5786-0659

Funding

Biodegradable nanoparticles, a genome editing platform to treat hemophiliaR01HL136652 · NHLBI · OHIO STATE UNIVERSITY · PI DONG, YIZHOU · 2017 to 2021
$2.3M
Cell-specific and multifunctional drug formulations for in vivo deliveryR35GM119679 · NIGMS · OHIO STATE UNIVERSITY · PI DONG, YIZHOU · 2016 to 2020
$1.9M
NHLBI NIH HHS R01 HL136652NIGMS NIH HHS R35 GM119679
6 · The paper itself

Abstract

RNA-based therapeutics have shown great promise in treating a broad spectrum of diseases through various mechanisms including knockdown of pathological genes, expression of therapeutic proteins, and programmed gene editing. Due to the inherent instability and negative-charges of RNA molecules, RNA-based therapeutics can make the most use of delivery systems to overcome biological barriers and to release the RNA payload into the cytosol. Among different types of delivery systems, lipid-based RNA delivery systems, particularly lipid nanoparticles (LNPs), have been extensively studied due to their unique properties, such as simple chemical synthesis of lipid components, scalable manufacturing processes of LNPs, and wide packaging capability. LNPs represent the most widely used delivery systems for RNA-based therapeutics, as evidenced by the clinical approvals of three LNP-RNA formulations, patisiran, BNT162b2, and mRNA-1273. This review covers recent advances of lipids, lipid derivatives, and lipid-derived macromolecules used in RNA delivery over the past several decades. We focus mainly on their chemical structures, synthetic routes, characterization, formulation methods, and structure-activity relationships. We also briefly describe the current status of representative preclinical studies and clinical trials and highlight future opportunities and challenges.

Indexed as

LipidsNanoparticlesBNT162 VaccineHumansLiposomesBNT162 VaccineLipid NanoparticlesLipidsLiposomes

Identifiers

PMID34279087
PMCPMC10088400

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.